No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-A brands, which are formulated to alleviate symptoms such as loose stools, diarrhea, vomiting, and ailments stemming from food or water contamination. Additionally, it provides specific tablets for diarrhea relief and quasi-pharmaceuticals like the Trumpet Intestinal Regulator BF. In its infection control segment, Taiko Pharmaceutical produces and supplies a range of sanitation products under the Cleverin brand to wholesalers. This includes the Cleverin generator, a device engineered to emit low concentrations of chlorine dioxide gas. The company also leverages its proprietary Cleverin technology by supplying it through original equipment manufacturer (OEM) agreements and engaging in joint product development ventures with other businesses. Its products are exported to several countries, including the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was founded in 1946 and is headquartered in Osaka, Japan.
www.seirogan.co.jpNo one on the platform currently holds 4574.T.
No tracked institution reports a position in 4574.T as of their last filing.
No one on the platform has traded 4574.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.7% | — | — | — | ||
| Rev. Growth % | 1.7% | -18.4% | ||||
| Profit Margin % | 14.4% | -43.4% | -14.1% | |||
| Free Cash Flow Margin % | 8.2% | -13.3% | -2.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6.3B | +3.4% | $1.80 | $1.80–$1.80 | — | 1 |
| 2027 | $6.4B | +0.8% | $2.40 | $2.40–$2.40 | — | 1 |
| 2028 | $6.5B | +3.0% | $5.00 | $5.00–$5.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 4574.TTaiko Pharmaceutical Co.,Ltd. | $258.00 | +1.18% | $13.0B | — |
| 4350.TMedical System Network Co., Ltd. | $505.00 | +1.00% | $14.8B | — |
| 4538.TFuso Pharmaceutical Industries,Ltd. | $2231.00 | +1.64% | $19.0B | — |
| 4579.TRaQualia Pharma Inc. | $568.00 | +1.43% | $13.9B | — |
| 4597.TSolasia Pharma K.K. | $29.00 | +0.00% | $7.9B | — |
| 4875.TMediciNova, Inc. | $305.00 | +4.81% | $15.0B | — |
| 6678.TTechno Medica Co., Ltd. | $2057.00 | +0.78% | $13.7B | — |
Source: Financial Modeling Prep · peers by sector/industry